Author

F. A. Lempp

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 5 Microbiology· 4 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 10 Research Focus:host-pathogen & immune response· 8 Organism:human· 7 Research Focus:cell type annotation· 3 Research Focus:drug response / drug discovery· 3 Assay:proteomics· 3 Organism:mouse· 2 Research Focus:cell signaling & trafficking· 1

Frequent Co-Authors

E. Cameroni· 7 shared H. Kaiser· 7 shared A. Telenti· 6 shared D. Pinto· 6 shared H. W. Virgin· 6 shared J. Noack· 6 shared J. Zhou· 6 shared B. Guarino· 5 shared

Activity by Year

2021-2023 · peak 6/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

7 shared papersImmunology

E. Cameroni

Mutual co-authors in cluster

Author profile →

10 papers

Recent·Most cited

Human pluripotent stem cell-derived hepatocyte-like cells for hepatitis D virus studies

H. Chi, B. Qu, A. Prawira, L. Maurer, J. Hu, R. M. Fu, F. A. Lempp, Z. Zhang, D. Grimm, X. Wu, S. Urban, V. L. Dao Thi

This study shows that hepatocyte-like cells derived from human pluripotent stem cells are permissive to hepatitis D virus infection and can be used to study HDV biology and test therapies.

bioRxiv · Oct 13, 2023 · PreprintMicrobiology

Therapeutic and vaccine-induced cross-reactive antibodies with effector function against emerging Omicron variants

A. Addetia, L. Piccoli, J. B. Case, Y.-J. Park, M. Beltramello, B. Guarino, H. Dang, D. Pinto, S. Scheaffer, K. Sprouse, J. Bassi, C. Silacci-Fregni, F. Muoio, M. Dini, L. Vincenzetti, , Fran

The paper shows that cross-reactive antibodies, like S309, retain effector functions against emerging Omicron variants despite reduced neutralization.

bioRxiv · Jan 17, 2023 · PreprintImmunology

The potent broadly neutralizing antibody VIR-3434 controls Hepatitis B and D Virus infection and reduces HBsAg in humanized mice

F. A. Lempp, T. Volz, E. Cameroni, F. Benigni, J. Zhou, L. E. Rosen, J. Noack, F. Zatta, H. Kaiser, S. Bianchi, G. Lombardo, S. Jaconi, H. Imam, L. B. Soriaga, N. Passini, , M. A. Schmid

This paper identifies a potent anti-HBs mAb, VIR-3434, that neutralizes HBV and HDV and reduces HBsAg and viremia in human liver-chimeric mice.

bioRxiv · Sep 9, 2022Microbiology

Robust and durable prophylactic protection conferred by RNA interference in preclinical models of SARS-CoV-2

Y. I. Anglero-Rodriguez, F. A. Lempp, J. McIninch, M. K. Schlegel, C. R. Brown, D. J. Foster, A. B. Castoreno, T. Nguyen, M. Subramanian, M. Montiel-Ruiz, H. Kaiser, A. Sahakyan, R. Spreafico, S. S. Morskaya, J. D. Barry, , V. Jadhav

This study identifies two siRNA combinations that provide robust prophylactic protection against SARS-CoV-2 in hamsters by reducing viral load and preventing lung pathology.

bioRxiv · Mar 20, 2022 · PreprintPharmacology & Toxicology

Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry

Y.-J. Park, A. De Marco, T. N. Starr, Z. Liu, D. Pinto, A. C. Walls, F. Zatta, S. K. Zepeda, J. E. Bowen, K. S. Sprouse, A. Joshi, M. Giurdanella, B. Guarino, J. Noack, R. Abdelnabi, , D. Veesler

This study identifies a broadly neutralizing antibody against sarbecoviruses that targets the ACE2 binding site and shows high resistance to escape mutations.

bioRxiv · Oct 13, 2021Immunology

A human antibody that broadly neutralizes betacoronaviruses protects against SARS-CoV-2 by blocking the fusion machinery

D. Pinto, M. M. Sauer, N. Czudnochowski, J. S. Low, M. A. Tortorici, M. P. Housley, J. Noack, A. C. Walls, J. E. Bowen, B. Guarino, L. E. Rosen, J. di Iulio, J. Jerak, H. Kaiser, S. Islam, , Lanzave

This paper identifies a human antibody that broadly neutralizes betacoronaviruses by targeting the stem helix, showing protection against SARS-CoV-2 and potential for vaccine design.

bioRxiv · May 9, 2021 · PreprintImmunology

Structural basis for broad sarbecovirus neutralization by a human monoclonal antibody

M. A. Tortorici, N. Czudnochowski, T. N. Starr, R. Marzi, A. C. Walls, F. Zatta, J. E. Bowen, S. Jaconi, J. di Iulio, Z. Wang, A. De Marco, S. Zepeda, D. Pinto, Z. Liu, M. Beltramello, , J. Bloom

This paper identifies a human monoclonal antibody that broadly neutralizes SARS-CoV-2 variants and zoonotic sarbecoviruses by targeting a conserved epitope on the spike protein.

bioRxiv · Apr 7, 2021 · PreprintImmunology

Antibodies to the SARS-CoV-2 receptor-binding domain that maximize breadth and resistance to viral escape

T. N. Starr, N. Czudnochowski, F. Zatta, Y.-J. Park, Z. Liu, A. Addetia, D. Pinto, M. Beltramello, P. Hernandez, A. J. Greaney, R. Marzi, W. G. Glass, I. Zhang, A. S. Dingens, J. E. Bowen, , Veesler

This study identifies antibodies against SARS-CoV-2 that balance neutralization potency and breadth, with some showing high resistance to viral escape.

bioRxiv · Apr 6, 2021 · PreprintMicrobiology

Membrane lectins enhance SARS-CoV-2 infection and influence the neutralizing activity of different classes of antibodies

F. A. Lempp, L. Soriaga, M. Montiel-Ruiz, F. Benigni, J. Noack, Y.-J. Park, S. Bianchi, A. C. Walls, J. E. Bowen, J. Zhou, H. Kaiser, M. Agostini, M. Meury, E. Dellota, S. Jaconi, , D. Corti

This study identifies membrane lectins that enhance SARS-CoV-2 infection and show how different antibodies neutralize infection through distinct mechanisms.

bioRxiv · Apr 3, 2021 · PreprintMicrobiology

The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2

A. L. Cathcart, C. Havenar-Daughton, F. A. Lempp, D. Ma, M. Schmid, M. L. Agostini, B. Guarino, J. Di iulio, L. Rosen, H. Tucker, J. Dillen, S. Subramanian, B. Sloan, S. Bianchi, J. Wojcechowskyj, , C. M. Hebner

This paper evaluates the in vitro and in vivo efficacy of dual-action monoclonal antibodies VIR-7831 and VIR-7832 against SARS-CoV-2, showing potent neutralization and reduced viral load in a hamster model.

bioRxiv · Mar 9, 2021 · PreprintImmunology